Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis.

https://read.qxmd.com/read/39907880/real-world-effectiveness-and-safety-of-rituximab-and-reduced-dose-chp-with-polatuzumab-vedotin-pola-r-chp-in-patients-aged-80-years-with-diffuse-large-b-cell-lymphoma-a-retrospective-analysis?uac=148436CN&ecd=wnl_readmost_250221&sso=true&redirected=slug